Effect of antioxidant (Edaravone) in spinal cord injury patients

Edaravone-based intervention in spinal cord injury through modulation of superoxide dismutase (SOD) and catalase (CAT) gene expression

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/02/007957

Enrollment

Registered

2017-02-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Spinal cord injury

Interventions

Intervention1: Edaravone: 30 mg in 500 ml saline twice a day for 14 days Control Intervention1: placebo: only 500 ml saline twice a day for 14 days

Eligibility

Inclusion criteria

Inclusion criteria: Age 16-65, either gender, Vertebral fracture T8-L1, Neurological Involvement (Association Impairment Scale (AIS-B-D), Duration of Injury < 72 hours.

Exclusion criteria

Exclusion criteria: Associated injuries such as limb fractures, thoraco-abdominal injuries, head injuries and Pre-existing central or peripheral neurologic diseases (i.e. previous stroke, radiculopathy or polyneuropathy) needing intervention were excluded.

Design outcomes

Primary

Measure	Time frame
Neurological recovery was assessed by AIS neurological grading and motor, sensory scores.Timepoint: The subjects were followed for 12 weeks and their neurological status recorded at baseline and at 4th and 12th week.	—

Secondary

Measure	Time frame
Adverse effectsTimepoint: upto 3 months	—

Countries

India

Contacts

Public ContactRajeshwar Nath Srivastava

Dept. of Orthopaedic Surgery, King Georgeâ??s Medical University, Lucknow, U.P., India

drrnsrivastava@yahoo.com9415054330

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026